Mirvaso Side Effects Center

Last updated on RxList: 1/5/2022
Mirvaso Side Effects Center

What Is Mirvaso?

Mirvaso (brimonidine) Topical Gel is an alpha-adrenergic agonist used to treat persistent (nontransient) skin redness (erythema) of rosacea in adults.

What Are Side Effects of Mirvaso?

Common side effects of Mirvaso include:

  • redness,
  • flushing,
  • burning sensation of the skin,
  • skin irritation,
  • warm feeling of the skin,
  • tingling sensation,
  • acne,
  • skin pain,
  • rosacea,
  • blurred vision,
  • headache,
  • runny nose, or
  • nasal congestion.

Skin redness and flushing may happen about 3 to 4 hours after you apply Mirvaso topical gel.

Dosage for Mirvaso

Apply a pea-size dose of Mirvaso once daily to each of the five areas of the face: central forehead, chin, nose, and each cheek. Mirvaso topical gel should be applied smoothly and evenly as a thin layer across the entire face avoiding the eyes and lips.

What Drugs, Substances, or Supplements Interact with Mirvaso?

Mirvaso may interact with beta-blockers, anti-hypertensives, cardiac glycosides, alcohol, barbiturates, opiates, sedatives, anesthetics, or monoamine oxidase (MAO) inhibitors. Tell your doctor all medications and supplements you use.

Mirvaso During Pregnancy or Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant before using Mirvaso; it is unknown if it will affect a fetus. It is unknown if Mirvaso passes into breast milk. Breastfeeding while using Mirvaso is not recommended.

Additional Information

Our Mirvaso (brimonidine) Topical Gel Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


See Images
Mirvaso Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using brimonidine topical and call your doctor at once if you have:

  • dizziness or feeling light-headed;
  • slow heartbeats; or
  • severe skin redness, burning, or other irritation.

Common side effects may include:

  • mild skin redness or burning;
  • flushing (warmth, redness, or tingly feeling); or
  • pale or lighter skin where the medicine was applied.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Rosacea, Acne, Shingles, Covid-19 Rashes: Common Adult Skin Diseases See Slideshow
Mirvaso Professional Information


The following adverse drug reactions are discussed in greater detail in other sections of the label:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

During clinical trials, 1210 subjects were exposed to MIRVASO topical gel. A total of 833 subjects were treated for persistent (nontransient) erythema associated with rosacea, and 330 of those were treated once daily for 29 days in vehicle-controlled trials.

Adverse reactions that occurred in at least 1% of subjects treated with MIRVASO topical gel once daily for 29 days and for which the rate for MIRVASO topical gel exceeded the rate for vehicle are presented in Table 1.

Table 1 - Adverse Reactions Reported in Clinical Trials by at Least 1% of Subjects Treated for 29 Days

Preferred Term MIRVASO Topical Gel (N=330)
n (%)
Vehicle Gel (N=331)
n (%)
Subjects with at least one adverse reaction, Number (%) of Subjects 109 (33) 91 (28)
  Erythema 12 (4%) 3 (1%)
  Flushing 9 (3%) 0
  Skin burning sensation 5 (2%) 2 (1%)
  Dermatitis contact 3 (1%) 1 (<1%)
  Dermatitis 3 (1%) 1 (<1%)
  Skin warm 3 (1%) 0
  Paraesthesia 2 (1%) 1 (<1%)
  Acne 2 (1%) 1 (<1%)
  Pain of skin 2 (1%) 0
  Vision blurred 2 (1%) 0
  Nasal congestion 2 (1%) 0

Open-Label, Long-Term Study

An open-label study of MIRVASO topical gel when applied once daily for up to one year was conducted in subjects with persistent (nontransient) facial erythema of rosacea. Subjects were allowed to use other rosacea therapies. A total of 276 subjects applied MIRVASO topical gel for at least one year. The most common adverse events (≥ 4% of subjects) for the entire study were flushing (10%), erythema (8%), rosacea (5%), nasopharyngitis (5%), skin burning sensation (4%), increased intraocular pressure (4%), and headache (4%).

Allergic Contact Dermatitis

Allergic contact dermatitis to MIRVASO topical gel was reported in approximately 1% of subjects across the clinical development program. Two subjects underwent patch testing with individual product ingredients. One subject was found to be sensitive to brimonidine tartrate, and one subject was sensitive to phenoxyethanol (a preservative).

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of MIRVASO topical gel. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or establish a causal relationship to drug exposure.

Cardiovascular disorders: bradycardia, hypotension (including orthostatic hypotension)

Immune system disorders: angioedema, hypersensitivity, lip swelling, swollen tongue, throat tightness, urticaria

Nervous system disorders: dizziness

Skin and subcutaneous disorders: pallor

Read the entire FDA prescribing information for Mirvaso (Brimonidine Topical Gel)


Rosacea usually first appears on the ________. See Answer

© Mirvaso Patient Information is supplied by Cerner Multum, Inc. and Mirvaso Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors